Natixis Bleichroeder Upgrades ZOLL Medical (ZOLL) to Buy
More News related to ZOLL
- ZOLL AutoPulse Cited for Improved Pre-Hospital Outcomes at AHA Scientific Sessions 2009
- ZOLL Medical's (ZOLL) LifeVest Discussed at American Heart Association 2009 Science Session
- ZOLL LifeVest Presented at AHA Scientific Sessions 2009
- Importance of Real-Time CPR Feedback Presented at AHA Scientific Sessions 2009
- Correction: ZOLL Medical Awarded Federal Supply Schedule Contract for Intravascular Temperature Management
More News related to Upgrades
- Davenport Upgrades Heinz (HNZ) to Buy
- First Analysis Upgrades Advisory Board Company (ABCO) to Overweight
- Jefferies & Co Upgrades Energy XXI (EXXI) to Hold
- Morgan Stanley Upgrades Iowa Telecom (IWA) to Equalweight
- Fox-Pitt Upgrades Eaton Vance (EV) to Outperform
Natixis Bleichroeder upgrades ZOLL Medical (Nasdaq: ZOLL) from Hold to Buy. Price target $25.
To see more analyst ratings on ZOLL Click Here.
ZOLL Medical Corporation, together with its subsidiaries, designs, manufactures, markets, and sells non-invasive resuscitation devices and related software solutions in the United States and internationally.
Related Categories
UpgradesStocks Mentioned
-0.14Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
